NCT06017518Recruiting
An Observational Study of Local Relapse After High Grade Osteosarcoma
Source: ClinicalTrials.gov · Last updated 22 Sept 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
multicenter retrospective and prospective study in patients with high-grade osteosarcoma
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 150 (estimated)
- First submitted
- 24 Aug 2023
- Start date
- 13 Jun 2022
- Primary completion date
- 30 Jun 2026
- Lead sponsor
- Istituto Ortopedico Rizzoli
- Diseases
- Childhood cancers, Sarcoma
- NCT number
- NCT06017518
What you commit to
- Study type: Observational
- Planned participants: 150
- From 13 Jun 2022 to the primary completion date, 30 Jun 2026
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Cases of LR demonstrated after \> 3 months after metastatic disease
Other
- Impossibility to ensure adequate compliance
Who the study is looking for
- Patients who experienced LR as first event of recurrence after treatment for localized high-grade osteosarcoma of bone, including cases with synchronous lung metastases
- Adequate patient compliance to follow-up visits
- Written informed consent prior to any study-specific analysis and/or data collection
- No age limits
Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| IRCCS Istituto ortopedico Rizzoli Coordinator of this site? Confirm its status | Bologna | Italy | Recruiting |
| Azienda Ospedaliero Universitaria Pisana Coordinator of this site? Confirm its status | Pisa | Italy | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.